Back to Search
Start Over
Author Correction: Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer
- Source :
- Nature Communications, Vol 13, Iss 1, Pp 1-1 (2022)
- Publication Year :
- 2022
- Publisher :
- Nature Portfolio, 2022.
- Subjects :
- Science
Subjects
Details
- Language :
- English
- ISSN :
- 20411723
- Volume :
- 13
- Issue :
- 1
- Database :
- Directory of Open Access Journals
- Journal :
- Nature Communications
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.0d2dddae1cc34582bd3de123927fce55
- Document Type :
- article
- Full Text :
- https://doi.org/10.1038/s41467-022-33355-0